Showing 6291-6300 of 7387 results for "".
- Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Todayhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-data-on-pv-10-to-be-presented-at-hemonc-today/2458972/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous
- New Officers Assume Roles with the American Academy of Dermatologyhttps://practicaldermatology.com/news/new-officers-assume-roles-with-the-american-academy-of-dermatology/2458976/Mark Lebwohl, MD, FAAD, a dermatologist in New York City, took office as president of the American Academy of Dermatology (AAD). Timothy G. Berger, MD, FAAD, a dermatologist in San Francisco, also assumed his position as vice president of the AAD. Drs. Lebwohl and Berger assumed office at the con
- Syneron Candela Launches "Changing Lives" Program At AADhttps://practicaldermatology.com/news/syneron-candela-launches-changing-lives-program-at-aad/2458985/Syneron Medical Ltd. is introducing the Changing Lives Program, a corporate wide initiative that the company says leverages its life-changing technologies with life-changing causes. Launching at the annual American Academy of Dermatology (AAD) meeting in San Francisco on March 21, Changing Lives&
- NuGene BioPharma, Inc. Acquires SkinGuardian®https://practicaldermatology.com/news/nugene-biopharma-inc-acquires-skinguardian/2458986/NuGene International, Inc.’s subsidiary corporation, NuGene BioPharma, Inc., has acquired all rights, title and interest in and to SkinGuardian®, an FDA-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream. NuGene BioPharma acquired all intellectual
- Nestlé Skin Health Announces Leadership Teamhttps://practicaldermatology.com/news/nestl-skin-health-announces-leadership-team/2458993/Nestlé Skin Health announced organizational changes at top management level to support the company’s expanded market opportunity and ambition. “Our goal is to grow the number of people the company serves to over a billion within 10 years, by offering skin health solutions that
- L'Oreal International Extends Deadline for Social Responsibility in Dermatology Awardshttps://practicaldermatology.com/news/loreal-international-extends-deadline-for-social-responsibility-in-dermatology-awards/2458996/L’Oréal announced today the extension of the closing date of its International Awards for Social Responsibility in Dermatology to April 15th 2015. Patients with dermatological conditions may frequently face discrimination and feel socially excluded,
- Three New CeraVe Baby Products Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/three-new-cerave-baby-products-awarded-national-eczema-association-seal-of-acceptance/2458995/Valeant Pharmaceuticals North America LLC is pleased to announce today that all three products in its newest product line, CeraVe® Baby, have been awarded the National Eczema Association (NEA) Seal of Acceptance™, which maintains rigorous standards for approval. Products include Ce
- Novel Anti-Biofilm AQUACEL™ Ag+ Dressing Demonstrates Positive Results in Hard-to-Heal Woundshttps://practicaldermatology.com/news/novel-anti-biofilm-aquacel-ag-dressing-demonstrates-positive-results-in-hard-to-heal-wounds/2458998/A new, multi-country, clinical evaluation study showed that AQUACEL™ Ag+ wound dressing demonstrated positive results in wounds, including those compromised by biofilm and/or infection. AQUACEL™ Ag+ dressings are designed to disrupt biofilm and kill infection-
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Pfizer Announces FDA Acceptance For Review of Supplemental New Drug Application for Oral Xeljanz For Plaque Psoriasishttps://practicaldermatology.com/news/pfizer-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-oral-xeljanz-for-plaque-psoriasis/2459011/The FDA accepted for review Pfizer Inc.’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) 5mg and 10mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to sever